UroGen Pharma Ltd. 4

Jason Drew Smith, General Counsel of UroGen Pharma Ltd., had 3,334 RSUs vest into ordinary shares and then sold 1,519 shares (mainly for tax withholding) at about $42.54 per share.

On September 7, 2026, Jason Drew Smith, General Counsel of UroGen Pharma Ltd., had 3,334 restricted stock units (RSUs) vest and convert into ordinary shares, increasing his direct holding to 54,660 shares before any sales. The following day, September 8, 2026, he sold 1,519 ordinary shares at an average price of approximately $42.54 per share, for proceeds of about $64,600, reducing his direct ownership to 53,141 shares. The Form 4 notes that these shares were sold to satisfy withholding tax obligations upon RSU settlement, indicating the transactions are largely routine compensation-related events rather than discretionary open-market purchases or sales.

Filing Facts

CIK

1668243

Ticker

URGN

Form

4

Source Type

fda

Accession

0001437749-26-029963

Alert Tier

5